Your browser doesn't support javascript.
loading
Damage measured by Damage Index for Antiphospholipid Syndrome (DIAPS) in antiphospholipid antibody-positive patients included in the APS ACTION registry.
Balbi, Gustavo G M; Ahmadzadeh, Yasaman; Tektonidou, Maria G; Pengo, Vittorio; Sciascia, Savino; Ugarte, Amaia; Belmont, H Michael; Lopez-Pedrera, Chary; Fortin, Paul R; Wahl, Denis; Gerosa, Maria; de Jesús, Guilherme R; Ji, Lanlan; Atsumi, Tatsuya; Efthymiou, Maria; Branch, D Ware; Nalli, Cecilia; Rodriguez Almaraz, Esther; Petri, Michelle; Cervera, Ricard; Knight, Jason S; Artim-Esen, Bahar; Willis, Rohan; Bertolaccini, Maria Laura; Cohen, Hannah; Roubey, Robert; Erkan, Doruk; de Andrade, Danieli Castro Oliveira.
Afiliación
  • Balbi GGM; Universidade de São Paulo, São Paulo, São Paulo, Brazil.
  • Ahmadzadeh Y; Universidade Federal de Juiz de Fora, Juiz de Fora, Minas Gerais, Brazil.
  • Tektonidou MG; Barbara Volcker Center for Women and Rheumatic Disease, Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, USA.
  • Pengo V; National and Kapodistrian University of Athens, Athens, Greece.
  • Sciascia S; University Hospital Padova, Padova, Italy.
  • Ugarte A; Center of Research of Immunopathology and Rare Diseases, University of Turin, Turin, Italy.
  • Belmont HM; Hospital Universitario Cruces, País Vasco, Barakaldo, Spain.
  • Lopez-Pedrera C; Hospital for Joint Diseases, New York University, New York, NY, USA.
  • Fortin PR; Rheumatology Service, IMIBIC/Reina Sofia Hospital, University of Cordoba, Cordoba, Spain.
  • Wahl D; CHU de Québec-Université Laval, Québec, Québec, Canada.
  • Gerosa M; Université de Lorraine, INSERM, DCAC, Nancy, France.
  • de Jesús GR; Vascular Medicine Division and Regional Competence Center for Rare Vascular and Systemic Autoimmune Diseases, CHRU-Nancy, Nancy, France.
  • Ji L; Clinical Immunology & Rheumatology Unit, IRCCS Istituto Auxologico Italiano, Milan, Italy.
  • Atsumi T; Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil.
  • Efthymiou M; Rheumatology and Immunology Department, Peking University First Hospital, Beijing, China.
  • Branch DW; Hokkaido University Hospital, Sapporo, Japan.
  • Nalli C; Haemostasis Research Unit, Department of Haematology, University College London, London, UK.
  • Rodriguez Almaraz E; University of Utah and Intermountain Healthcare, Salt Lake City, UT, USA.
  • Petri M; Rheumatology and Immunology Unit, ASST Spedali Civili of Brescia, Brescia, Italy.
  • Cervera R; Hospital Universitario, 12 de Octubre, Madrid, Spain.
  • Knight JS; Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Artim-Esen B; Department of Autoimmune Diseases, Hospital Clínic, Barcelona, Catalonia, Spain.
  • Willis R; Division of Rheumatology, University of Michigan, Ann Arbor, MI, USA.
  • Bertolaccini ML; Istanbul University School of Medicine, Istanbul, Turkey.
  • Cohen H; Antiphospholipid Standardization Laboratory, University of Texas Medical Branch, Galveston, TX, USA.
  • Roubey R; Academic Department of Vascular Surgery, King's College London British Heart Foundation Centre of Excellence, School of Cardiovascular Medicine & Sciences, London, UK.
  • Erkan D; Haemostasis Research Unit, Department of Haematology, University College London, London, UK.
  • de Andrade DCO; University of North Carolina, Chapel Hill, NC, USA.
Rheumatology (Oxford) ; 63(3): 772-779, 2024 Mar 01.
Article en En | MEDLINE | ID: mdl-37307082
ABSTRACT

OBJECTIVES:

Our primary objective was to quantify damage burden measured by Damage Index for Antiphospholipid Syndrome (DIAPS) in aPL-positive patients with or without a history of thrombosis in an international cohort (the APS ACTION cohort). Secondly, we aimed to identify clinical and laboratory characteristics associated with damage in aPL-positive patients.

METHODS:

In this cross-sectional study, we analysed the baseline damage in aPL-positive patients with or without APS classification. We excluded patients with other autoimmune diseases. We analysed the demographic, clinical and laboratory characteristics based on two subgroups (i) thrombotic APS patients with high vs low damage; and (ii) non-thrombotic aPL-positive patients with vs without damage.

RESULTS:

Of the 826 aPL-positive patients included in the registry as of April 2020, 586 with no other systemic autoimmune diseases were included in the analysis (412 thrombotic and 174 non-thrombotic). In the thrombotic group, hyperlipidaemia (odds ratio [OR] 1.82; 95% CI 1.05, 3.15; adjusted P = 0.032), obesity (OR 2.14; 95% CI 1.23, 3.71; adjusted P = 0.007), aß2GPI high titres (OR 2.33; 95% CI 1.36, 4.02; adjusted P = 0.002) and corticosteroid use (ever) (OR 3.73; 95% CI 1.80, 7.75; adjusted P < 0.001) were independently associated with high damage at baseline. In the non-thrombotic group, hypertension (OR 4.55; 95% CI 1.82, 11.35; adjusted P = 0.001) and hyperlipidaemia (OR 4.32; 95% CI 1.37, 13.65; adjusted P = 0.013) were independent predictors of damage at baseline; conversely, single aPL positivity was inversely correlated with damage (OR 0.24; 95% CI 0.075, 0.77; adjusted P = 0.016).

CONCLUSIONS:

DIAPS indicates substantial damage in aPL-positive patients in the APS ACTION cohort. Selected traditional cardiovascular risk factors, steroids use and specific aPL profiles may help to identify patients more prone to present with a higher damage burden.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Síndrome Antifosfolípido / Hiperlipidemias Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Rheumatology (Oxford) Asunto de la revista: REUMATOLOGIA Año: 2024 Tipo del documento: Article País de afiliación: Brasil

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Síndrome Antifosfolípido / Hiperlipidemias Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Rheumatology (Oxford) Asunto de la revista: REUMATOLOGIA Año: 2024 Tipo del documento: Article País de afiliación: Brasil